Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 9/20 | 0.41 |
| ▸ | ACVRL1 | P37023 | 9/20 | 0.41 |
| ▸ | RET | P07949 | 4/20 | 0.41 |
| ▸ | ROS1 | P08922 | 4/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | RHEB | Q15382 | 2/20 | 0.37 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 5/20 | 0.35 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.35 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.35 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL768012 | 0.89 | NTRK1 (0.45) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL438772 | 0.81 | NTRK1 (0.45) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL768013 | 0.81 | NTRK1 (0.42) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL773873 | 0.80 | NTRK1 (0.44) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL13692336 | 0.80 | NTRK1 (0.43) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL773933 | 0.80 | NTRK1 (0.43) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL773578 | 0.80 | NTRK1 (0.43) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL439680 | 0.79 | NTRK1 (0.61) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL793656 | 0.79 | NTRK1 (0.49) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL774038 | 0.79 | NTRK1 (0.43) | NTRK1ACVRL1RETROS1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | NTRK1 718/4885ACVRL1 3502/4885RET 16/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | NTRK1 718/4885ACVRL1 3502/4885RET 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.